NEIL GARRY ARTHUR 4

What Happened
Neil Garry Arthur, a director of Celldex Therapeutics (CLDX), was granted a 26,000-share derivative award on June 25, 2026. The Form 4 reports the acquisition as 26,000 shares at $0.00 (derivative), with a footnote stating the award is an option granted under the company's 2021 Omnibus Equity Incentive Plan. This is a grant of equity compensation (not a cash purchase or sale) and does not represent an immediate cash value on the Form 4.

Key Details

• Transaction date: 2026-06-25 (reported on Form 4 filed 2026-06-29)
• Transaction type/code: A (award/grant); 26,000 shares acquired as a derivative; price reported $0.00
• Footnote: F1 — Option granted pursuant to the 2021 Omnibus Equity Incentive Plan
• Shares owned after transaction: Not specified in the supplied filing details
• Timeliness: Form 4 filed 2026-06-29 (within the required two business days), so the filing appears timely

Context
This filing reports an option-style award to a director as routine equity compensation. Because it is a derivative grant, it does not necessarily confer immediate economic value and may be subject to vesting and exercise terms (details not provided in the Form 4 excerpt). Such grants are common for board compensation and should be interpreted differently from open-market purchases or sales.